Arylmethylamino steroids as antiparasitic agents by Krieg, Reimar et al.
ARTICLE
Received 7 Jun 2016 | Accepted 3 Jan 2017 | Published 17 Feb 2017
Arylmethylamino steroids as antiparasitic agents
Reimar Krieg1, Esther Jortzik2, Alice-Anne Goetz3, Ste´phanie Blandin3, Sergio Wittlin4,5, Mourad Elhabiri6,
Mahsa Rahbari2, Selbi Nuryyeva6,7, Kerstin Voigt8, Hans-Martin Dahse8, Axel Brakhage8, Svenja Beckmann9,
Thomas Quack9, Christoph G. Grevelding9, Anthony B. Pinkerton10,11, Bruno Scho¨necker12, Jeremy Burrows13,
Elisabeth Davioud-Charvet6, Stefan Rahlfs2 & Katja Becker2
In search of antiparasitic agents, we here identify arylmethylamino steroids as potent
compounds and characterize more than 60 derivatives. The lead compound 1o is fast acting
and highly active against intraerythrocytic stages of chloroquine-sensitive and resistant
Plasmodium falciparum parasites (IC50 1–5 nM) as well as against gametocytes. In P. berghei-
infected mice, oral administration of 1o drastically reduces parasitaemia and cures the
animals. Furthermore, 1o efﬁciently blocks parasite transmission from mice to mosquitoes.
The steroid compounds show low cytotoxicity in mammalian cells and do not induce acute
toxicity symptoms in mice. Moreover, 1o has a remarkable activity against the blood-feeding
trematode parasite Schistosoma mansoni. The steroid and the hydroxyarylmethylamino
moieties are essential for antimalarial activity supporting a chelate-based quinone methide
mechanism involving metal or haem bioactivation. This study identiﬁes chemical scaffolds
that are rapidly internalized into blood-feeding parasites.
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M
alaria caused by the unicellular apicomplexan parasite
Plasmodium still threatens about 3.2 billion people
worldwide. In 2015 there were an estimated 214 million
cases of malaria and 438,000 deaths1. Artemisinin-based
combination therapies are the currently recommended
treatment for uncomplicated P. falciparum malaria1, however,
parasites exhibiting artemisinin-resistance have now been
reported2,3. Thus, the discovery and development of novel
antimalarials and transmission-blocking agents is of global
importance4,5. Schistosomiasis (bilharzia) ranks second to
malaria as a parasitosis affecting more than 240 million people
in the tropics and subtropics6. A vaccine against these parasites is
not yet available, and praziquantel (PZQ) is the only commonly
used drug for treatment, justifying the fear of upcoming
resistance7.
In connection with our work on steroids as chiral ligands for
metal ions8 we became interested in the biological activity of
steroid compounds. In general, steroids possess a conformation
of their lipophilic framework, which allows the placement
of substituents in well-deﬁned spatial environments and
conformational freedom. Also, there is a great structural
variability of the tetracyclic framework, including estratrienes,
androstanes, and cholestanes. In addition, ring junctions
(5a/5b, 14a/14b and so on) can differ considerably. Functional
groups can be attached at up to 27 positions in the framework
or on side chains, and advances in synthetic chemistry over
the last several years have made accessing many of these
derivatives possible. In addition to their use in pharmaceuticals,
there has also been growing interest in the use of steroid
derivatives as rigid homochiral model compounds, for example,
biomimetics, or as templates for chemo-, regio- and
stereoselective investigation. Thus, one approach to discover
new biologically active compounds is to combine a steroid
skeleton with structural elements possessing appropriate
biological activities.
Interestingly, during a screening program for potential
antiprotozoal drugs, the naturally occurring steroid 3b-amino-
22,26-epiminocholest-5-ene (sarachine) from the leaves of Saraca
punctate, had been isolated as a hit. Despite its simple
substitution patterns, it was reported to exhibit activity against
the malaria parasite Plasmodium falciparum9, and a series of
amino steroids having side chains similar to that of sarachine
were prepared from deoxycholic acid as the starting material10.
To this end, the most active derivative of this series contained
a chloroquinoline moiety in the side chain, which might be
contributing to biological activity. The advantage of employing
hydrophobic steroid units is their membrane permeability, paving
the way for biologically active hybrid molecules. On the basis of
this knowledge o-pyridiniumalkyl ethers of steroidal phenols
were synthesized and indeed the combination of the hydrophobic
steroid moiety with a hydrophilic group (ferrocenylmethylamino
group, N-alkyl-pyridinium groups)11,12 led to compounds
with antimicrobial activity. In continuation of this work, the
3-methoxy-estra-1,3,5(10)-triene unit was combined with the
o-hydroxybenzylamino group13 and resulted in compounds
with antimalarial activity which were systematically optimized
using structure-activity relationship approaches.
Here we report on arylmethylamino steroids with excellent
antimalarial activity. The compounds are active in vitro against
human and murine Plasmodium asexual blood stages as well as
against P. falciparum gametocytes. Furthermore they exhibit
in vivo activity in Plasmodium berghei-infected mice and block
the transmission of parasites to mosquitoes. Notably the
compounds also have fatal effects on adult Schistosoma mansoni.
The lipophilic steroid carrier of these antiparasitic lead
compounds is likely to facilitate membrane permeation and
bioavailability whereas the essential hydroxyarylmethylamino
moiety points to a chelate-based quinone methide mechanism
involving metal or haem bioactivation.
Results
Chemistry. The low molecular weight steroid compounds
described here are based on a substituted steroidal pharmaco-
phore and represent novel chemical matter14. All compounds are
derived from amino steroids with varying constitutions of the
basic gonane core (series 1–14) and varying functional groups
R (substitution patterns c, e, g, i, k, m, q, s, u and w, Fig. 1).
In brief, the compounds were synthesized via condensation of
amino steroids with arylaldehydes, and subsequent NaBH4-
reduction of obtained Schiff-bases furnished the desired
compounds in high yields. The synthesis could also be carried
out as a one-pot procedure without isolation of Schiff-bases. This
is especially beneﬁcial in case of cis-conﬁgured amino alcohols
(series 5, 8, 11 and 14) where reaction with aldehydes leads to
rapidly exchanging tautomeric Schiff-based/oxazoline equilibria.
Complete synthetic details can be found in Supplementary
Note 1, 1H and 13C NMR spectra of the most relevant
compounds are provided in Supplementary Figs 1–6.
Activity against Plasmodium falciparum blood stages in vitro.
The activity of the steroid compounds was tested against the asexual
blood stages of the malaria parasite P. falciparum (strain 3D7) in
the 3H-hypoxanthine incorporation assay. As shown in Table 1, the
compounds are highly active against red blood cell stages of P.
falciparum with IC50 values in the nanomolar range. The most
active compound 1o had an IC50 value of 4.1±1.6 nM on 3D7
(n¼ 6), (± indicates s.d. throughout the manuscript, unless
otherwise stated) which is comparable to the in vitro activity of
clinically employed antimalarials such as chloroquine (IC50¼ 8.6
nM) and artemisinin (IC50¼ 17.3 nM) using the same methods
(72h 3H-hypoxanthine incorporation assay)15. The second most
active compound 2o showed an IC50 value of 6.6±2.1 nM (n¼ 4)
on 3D7 (for data on all compounds tested, please see
Supplementary Table 1). Notably, the compounds were found to
be more active against chloroquine-resistant parasites as tested for
the P. falciparum strain Dd2: 1o: 1.0±0.9 nM (n¼ 4); 2o:
2.0±1.2 nM (n¼ 4); chloroquine: 90.2 nM; artemisinin: 20.4 nM
(ref. 15) (Supplementary Fig. 7). A similar phenomenon has been
reported for other antimalarial compounds as diverse as 8-
aminoquinolines and amadantine. The underlying mechanism of
this very promising activity of the steroid compounds deserves
further attention.
To assess the rapidity of growth inhibition induced by the
steroid compounds, the so-called IC50 speed assay16 was
conducted for compound 1o on P. falciparum NF54 (Fig. 2a,b).
In this assay, a comparison of IC50 values, which are obtained
side-by-side after 72, 48, and 24 h of compound incubation, is
carried out (the 72 h assay is the standard IC50 assay otherwise
used in our study). For compound 1o, no signiﬁcant IC50 shifts
were determined across all time points, indicating that the
compound is fast acting like chloroquine or artesunate and not
slow acting like pyrimethamine.
To further study the mechanism of action of the steroid
compounds and evaluate the potential involvement of redox
stress, compound 1o was tested in cell culture on the
chloroquine-sensitive P. falciparum 3D7 strain expressing the
cytosolic glutathione redox sensor hGrx1-roGFP2
(Supplementary Note 2). As indicated in Supplementary Fig. 8,
24 h incubation with 20, 50 and 100 nM of compound 1o led
to a dose-dependent increase of the redox ratio of the probe,
pointing to increased oxidation and alterations in the intracellular
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redox potential. Although these results fell short in reaching
signiﬁcance in the experimental setup chosen, they point towards
a potential inﬂuence of compound 1o on the glutathione redox
homeostasis, which deserves to be studied in more detail.
Activity against P. berghei in vivo and acute toxicity.
Compounds with the highest activity in the P. falciparum cell
culture were tested in an in vivo mouse model (P. berghei) at the
Swiss TPH as previously described17–19 (Supplementary Table 2).
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Figure 1 | Formulas of compounds investigated. (a) Basic structures and (b) corresponding substituents.
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Initially, the compound 2c was tested, which exhibited an IC50
of 73 nM against P. falciparum 3D7 in vitro. The compound was
active when applied to the mice subcutaneously (s.c.) or orally
over three consecutive days. Subcutaneous application of
3 10mg kg 1 reduced parasitaemia by 47% and increased
the life span of the animals from 6 days to 10 days
(parasitized control mice were killed on day 4 to prevent death
otherwise occurring at day 6); 3 30mg kg 1 s.c. reduced
parasitaemia by 87% and increased the life span from 6 to
14 days. After oral application of 3 100mg kg 1 2c,
parasitaemia decreased by 99%, and survival time increased to
16 days. As shown in Supplementary Table 2 compounds 1c and
1o (optimized on the basis of 2c) were studied in more detail.
Compound 1c, which had an in vitro activity against
P. falciparum 3D7 of 7.4 nM, was also active after s.c. and oral
application and showed a similar in vivo activity pattern as 2c.
Parasitaemia was drastically decreased, and the life span of the
animals was enhanced.
Before carrying out further P. berghei in vivo experiments,
compound 1o, which had the best in vitro activity against
P. falciparum 3D7 (72 h incubation, IC50¼ 4.1 nM) and a strong
activity against P. berghei ex vivo (24 h incubation,
IC50¼ 3.1±2.4 nM (n¼ 3) and methylene blue which served as
a control resulted in 2.6±1.2 nM (n¼ 3)), were tested in an ‘acute
toxicity’ in vivo model. The compound was applied at an
accumulative dose of 100mg kg 1 (per os (p.o.). as well as
intraperitoneally (i.p.)). The ﬁrst application was 5mg kg 1, 2 h
later 15mg kg 1, 2 h later 30mg kg 1 and again 2 h later
50mg kg 1. No acute toxicity symptoms were observed in that
experiment. Moreover, we performed pharmacokinetics studies in
mice, dosing i.v., i.p. and p.o. (Supplementary Table 5).
1o displayed moderate clearance (29.6mlmin 1 kg 1) with
a long half-life (48 h) after i.v. dosing. The compound showed
modest oral bioavailability (%Fo5) but sustained plasma levels of
B100 nM after oral dosing at 100mg kg 1. In contrast,
high exposure and sustained levels of B2mM were obtained
after i.p. dosing at 100mg kg 1. On the basis of these data, we
decided to perform the following P. berghei in vivo experiments
at doses of 4 100mg kg 1. After i.p. administration of
4 100mg kg 1 1o, all mice treated were cured; after oral
administration two thirds of the animals were cured, which is
consistent with the improved exposure after i.p. dosing. Notably,
a single dose (1 100mg kg 1) p.o. also reduced parasitaemia
by 98.46% and increased the life span from 6 to 14 days.
Effects on transmission and gametocytes. We further tested the
activity of compound 1o on parasite transmission from mice to
Anopheles gambiae mosquitoes. For this, P. berghei-infected mice
Table 1 | Antiplasmodial effects as well as antiproliferative and cytotoxic activity of selected steroid compounds on mammalian
cells.
Compound Antiplasmodial activity Antiproliferative activity Cytotoxicity
IC50 [nM] GI50[lM] CC50[lM]
Pf (3D7) HUVEC GI50 K-562 GI50 HeLa CC50
1c 7.4 17.1 5.9 4128
1o 4.1 108.5 5.0 4113
2c 73 10.0 5.1 42.9
2o 6.6 13.8 2.5 4113
3c 42 4.1 3.8 20.7
4c 63 3.1 2.6 12.0
5c 160 2.2 2.0 11.3
6c 676 4.4 2.5 11.3
7c 120 1.2 2.0 10.1
8c 224 2.5 0.5 5.9
9c 999 11.2 8.4 48.8
10c 84 2.9 2.5 11.5
11c 141 22.0 0.1 6.4
12c 4,360 12.4 16.5 38.0
13c 465 23.7 17.7 85.3
14c 208 6.7 8.2 21.8
STS 948 551 7.2 6.6 18.3
Strong antiproliferative effects are judged to occur at a GI50: r2 mM. All values are mean values of at least three independent determinations that differed by less than 20%. SDs for antiplasmodial
activity are provided.
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is a slow-acting compound.
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received a daily injection of compound 1o for 3 days starting
24 h post passage and were exposed to mosquito bites 24 h after
each injection. Tween 80 (Tw80) and methylene blue (MB) served
as negative and positive controls, respectively. As with MB,
compound 1o limited parasite multiplication in mice, albeit to
a lesser extent (Fig. 3a). Importantly, three doses were sufﬁcient
to fully block parasite transmission to mosquitoes (Fig. 3b,c,
4 days post passage). A reduction of parasite transmission to
mosquitoes was already visible 24 h after the ﬁrst treatment
(Fig. 3b,c, 2 days post-passage), with reduced infection prevalence
and parasite loads in mosquitoes fed on compound 1o-treated
mice compared with control mice.
Parasite gametocytes are the only stage infectious to mosqui-
toes. To determine whether compound 1o has any activity on
these sexual stages, we exposed P. falciparum gametocytes to drug
treatment at different times during their maturation. A strong
reduction of gametocyte viability was observed for all stages after
exposure to low concentrations of compound 1o (relative survival
below 50% for concentrations45 nM), although we never
detected complete killing of gametocytes, even at concentra-
tions41 mM (Fig. 3d). The fact that early stage gametocytes
survived better at 100 mM than at 1 mM suggests that at high
concentrations, the compound could have a gametostatic activity.
Taken together, these data and the activity of compound
1o against P. berghei asexual parasites ex vivo suggest that
the transmission blocking effect observed above is explained
by a combination of the activity of 1o on gametocytes and
a reduced gametocytemia following the impairment of asexual
stages, and/or a decrease in gametocyte commitment on
treatment.
Antimicrobial proﬁle and effects on Schistosoma mansoni. To
learn more about speciﬁcity and potential application of
the steroid compounds, the two best compounds 1o and 2o were
tested for their antimicrobial spectrum at the Hans Kno¨ll
Institute, Jena (Supplementary Tables 3 and 4). The compounds
showed moderate activity against selected bacteria and
weak activity against fungi. Antimicrobial activity was detectable
in 4 out of 11 cases (Escherichia coli, Mycobacterium vaccae,
Sporobolomyces salmonicolor and Candida albicans); however,
micromolar concentrations of the compounds were required.
No biologically relevant inhibition was determined for Bacillus,
Pseudomonas, Staphylococcus, Enterococcus or Penicillium
(Supplementary Table 3). The antifungal proﬁle against 6 asco-
mycetes and 2 zygomycetes indicated weak activity only
(Supplementary Table 4).
Interestingly, however, the steroid compounds were found to
have remarkable physiological and morphological effects on
adult Schistosoma mansoni, leading to the death of this
trematode parasite in vitro. To investigate the effects of the
compounds 1o, 2o and 1c in more detail, we made use of an
established in vitro culture for adult S. mansoni20. The three
compounds were tested in concentrations of 1–100 mM each,
and their effects were ﬁrst checked via bright-ﬁeld microscopy
with respect to physiological parameters such as pairing stability,
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Figure 3 | Effect of compound 1o on P. berghei multiplication in mice and on parasite transmission to mosquitoes. (a) Naive mice were injected i.v. with
infected blood and treated daily for 3 days starting 24 h post passage with compound 1o (100mg kg 1), with methylene blue (MB, 15mg/kg), or with
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gametocytes was calculated for each concentration relative to parasites exposed to vehicle.
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egg production, and survival. Starting with 1 mM (1c, 2o) and
5 mM (1o), respectively, all compounds showed a negative
inﬂuence on worm physiology. Using 10 mM and more, the
most remarkable effects on all three parameters were observed
with 2o, followed by 1c and 1o. Using 2o, reduced motility
and viability were observed starting at 1 mM, while 10 mM of
this compound caused the death of the parasites within a week
(Supplementary Fig. 9). This was accompanied by tegumental
invaginations and oedema-like swellings of the body. CLSM
indicated an enlarged gut lumen and degradation of
the gastrodermis, which led to the accumulation of degraded
tissue and aggregate formation. Furthermore, we observed
a disorganization of oocytes within the ovary and reduced sizes
of testicular lobes in males (see Fig. 4 and detailed explanations in
the legend).
All tested compounds affected physiology and morphology in
S. mansoni that included changes in the female ovary as well
as in the gut of both genders, ﬁnally leading to the death of the
blood ﬂuke. Interesting was the tissue dilatation of the gut
associated with the degradation of the gastrodermis and the
accumulation of particle aggregates of remarkable size. In this
intensity, such a phenotype has not yet been observed with
other substances applied to adult schistosomes in vitro20,
although it resembled a phenotype previously observed for
adults treated with imatinib or its derivatives dasatinib or
nilotinib to some extent. However, in none of the latter cases
were tegumental invaginations or a tissue dilatation of this
intensity observed, nor such a strong accumulation of aggregates.
It should further be noted that in comparison with a unicellular
organism such as Plasmodium, it usually takes much higher drug
concentrations (accompanied by lower selectivity indices) to
target multicellular organisms such as Schistosoma. In the case of
the arylmethylamino steroids, lower micromolar concentrations
were required to see clear effects on schistosomes. This is
exactly in the range of the gold standard praziquantel, which is
toxic for schistosomes at 5–10 mM but no longer at 1 mM
in vitro21.
Cytotoxicity and pharmacokinetic parameters. Selected steroid
compounds were tested for their antiproliferative activity in
HUVEC cells and K-562 cells with GI50-values between 0.1 and
108.5 mM. Cytotoxicity tests were carried out on HeLa
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were investigated via confocal laser scanning microscopy. (a–c) Untreated
schistosome couples exhibiting a smooth tegumental surface with
tubercles. (a) The testes are composed of lobes containing spermatogonia
and differentiated spermatozoa accumulating in the sperm vesicle. (b) The
gut lumen is surrounded by the gastrodermis. (c) The ovary of the female
exhibits a bulb-like structure with mature oocytes at the broader, posterior
part and immature oocytes at the narrow, anterior part. (d,e) The ootype is
the egg-forming organ. (d–i) 1o (9-day treatment); swellings and
invaginations occurred at the tegument. Arrows mark aggregates of
degradation products of the gastrodermis within the gut lumen. (f) The
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part of the ovary, which normally only contains immature oocytes.
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swellings, gastrodermis degradation, and aggregate formation were visible.
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spermatozoa within the seminal vesicle were reduced. (n) The morphology
of the ovary was disturbed, (o) and eggs were deformed. (p–u) 1c (5 mM;
9-day treatment); (p) diameter of the testicular lobes and ovary appeared
normal, number of mature oocytes was smaller. (p,q) Aggregate-like
degradation products of the gastrodermis occurred within the gut lumen;
size of aggregates was larger in males (p,q) than in females (r). Gut
swelling and tegument invaginations were not obvious. (s) After 13-day
treatment, the diameter of the testicular lobes was reduced. (t,u) Gut
swelling and tegument invagination appeared. Morphology of ovary was
disturbed and number of mature oocytes reduced. (s–u) Degradation
aggregates appeared within gut lumen and oesophagus area. After 9 days,
precipitates were larger in males (s,t) compared with females (u). E, egg;
F, female; G, gut; Ga, gastrodermis; Gy, gynecophoral canal; Hs, head
sucker; M, male; T, testis; Te, tegument; Tu, tubercle: O, ovary; Oe,
oesophagus; mO, mature oocytes; iO, immature oocytes; Oo, ootype;
Sv, seminal vesicle; Vs, ventral sucker. Scale bars, 100mm, except
d (400mm) and o (50mm).
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cells, resulting in CC50-values between 5.9 and 4128 mM,
which is 2–4 orders of magnitude higher than the IC50 values
determined against malaria parasites (Table 1). In addition,
cytotoxicity tests with compound 1o were carried out on
immortalized human hepatocytes, Fa2N-4 cells, resulting in an
LC50450mM. The best compound 1o has furthermore
been tested in an acute toxicity in vivo model at the Swiss
Tropical Institute, Basel. The compound was applied at an
accumulative dose of 100mg kg 1 (p.o. as well as i.p.), but no
acute toxicity symptoms were observed.
First pharmacokinetic data for the best compound 1o were
collected at the Sanford Burnham Prebys Medical Discovery
Institute (Supplementary Table 6). Aqueous solubility, plasma
stability, plasma protein binding, hepatic microsome stability,
and membrane permeability using the parallel artiﬁcial
membrane permeability assay (PAMPA) were determined.
Although compound 1o was found to have rather poor aqueous
solubility (o1 mgml 1 across a range of pH), it displayed
good stability in plasma (62 and 58% remaining, respectively,
after a 3 h incubation with human and mouse plasma) and
moderate microsomal stability (B38% remaining after a 1 h
incubation with human or mouse liver microsomes).
Inﬂuence of metal or haem binding and catalysis. To gain more
insight into the mechanism of action of the steroid compounds,
the binding capacities of the most potent compounds 1o and
2o towards Cu(II) and Fe(III) were ﬁrst evaluated under
quasi-physiological experimental conditions (pH 7.5). Both
compounds were shown to lead to 1:1 stoichiometric complexes
with stability constants log KLM (L¼ 1o or 2o, M¼Cu(II)
or Fe(III)) ranging from¼ 4.1 to 4.7 (Supplementary Note 3,
Supplementary Fig. 17, and Supplementary Methods).
Compounds 1o and 2o share the same bidentate N,O binding
site suitable for speciation of soft divalent or hard trivalent
metal ions.
Interestingly, the most potent antimalarial compounds
(1o and analogues found in the present work) are the ortho-
substituted derivatives, suggesting that generation of radicals is
the most probable explanation for the increased efﬁcacy of the
chemical series. Similar ortho-substituted ligands of transient
metal complexes, such as the reduced benzoylmenadione
metabolite of the antimalarial plasmodione, which presents an
oxygen-rich bidentate site suitable for Fe(III) chelation22, were
reported to become redox-inactive when their effects were
antagonized with the known iron(III) chelator desferoxamine
(DFO). In this study a most potent antagonistic effect
(sum FIC50¼ 2.4) induced by DFO was observed when
combined with plasmodione in cell culture assays using RBCs
parasitized by P. falciparum 3D7.
In parallel, the ability of a broader range of compounds
(1o, 2o, 1a and 1h, used as a negative control, see Fig. 1) to
interact with haem was evaluated (Supplementary Note 3,
Supplementary Table 7, Supplementary Figs 10–16 and
Supplementary Methods). Regardless of the nature of the
compound, strong interactions (KD in the mM range) with the
haem dimer were measured (that is, haematin predominates
as a p-p dimer in solution at pH 7.5) and compare well
with chloroquine CQ, a well-known antiparasitic drug that acts
as a haemozoin inhibitor. p-p-interactions and hydrophobic
interactions are likely the driving forces accounting for such
strong interactions. It therefore appears that 1o and 2o displaying
an N,O bidentate site are capable of interacting with electroactive
metal ions such as Cu(II) or Fe(III). With respect to haem
ligation, the steroid unit was demonstrated to be of great
importance. The capacities of these systems to prevent haemozoin
formation were then investigated using the ESI-MS collision-
induced dissociation method. Interestingly, 1o (DV50¼ 289V,
bottom plateau of 20% at 400V) and 2o (DV50¼ 280V,
bottom plateau of 21% at 400V) were found to be the most
potent compounds to prevent haemozoin crystallization and are
better than the well-known antiparasitic drugs chloroquine
(DV50¼ 201V, bottom plateau of 0% at 400V) or amodiaquine
(DV50¼ 212V, bottom plateau of 7% at 400V). The signiﬁcant
residual amount of haem 1o or haem 2o adducts at a high
fragmentor voltage of 400V is indicative of covalent binding,
likely through quinone methide formation23 and cross-linking to
haem. The 2-hydroxyarylmethylamino moiety was further
demonstrated to be of crucial importance since model
compounds 1a and 2a, which are lacking such an electroactive
unit, are less efﬁcient. The covalent character of the haem adducts
observed with 1o and 2o was further substantiated by
co-incubation of the compounds and haem at pHo1 followed
by ESI-MS.
In conclusion, 1o and 2o bearing a 2-hydroxyarylmethylamino
moiety are potent metal (copper or iron) chelators and
likely covalently associate with haematin via quinone methide
formation and subsequent cross-linking. No signiﬁcant difference
has been found between 1o and 2o, showing that steroid
conformation is not of crucial importance. However, the presence
of the steroid moiety has been clearly demonstrated to favour
the physiochemical properties towards inhibition of haemozoin
formation, leading to increased antimalarial activities of both
lead agents. On the basis of these data and taking into account
the fact that parasitized red blood cells contain high amounts
of haem and free iron, it can be estimated that more
than 80% of compound 1o is present in complexed form within
the infected RBC (Supplementary Note 4 and Supplementary
Fig. 18).
Discussion
We identiﬁed and characterized arylmethylamino steroids
as a class of compounds with remarkable activity against malaria
parasites and schistosomes. Transmission-blocking activity, oral
availability, and low cytotoxicity further support their potential.
The presently synthesized and available compound pool
comprises about 60 steroid derivatives and a series of
non-steroidal analogues that can be employed for SAR studies
and considerations concerning a lead structure for further
optimization (Fig. 5). Present SAR data indicate that the
hydrophobic steroid component and a hydroxyarylmethylamino
group are essential for the antimalarial action of the compounds.
This gives rise to some key considerations (Fig. 5): the delivery
of small molecules to living cells is typically mediated by
polymers, lipids, sophisticated nano-sized drug delivery
systems24, or by altering membrane permeability, for example,
via covalent conjugation of target molecules with cholane
derivatives25. In our context, the lipophilic steroid moiety is
considered to mediate cellular uptake and intracellular transport
processes. Steroid conjugates often readily enter living cells,
either via membrane association and/or endocytotic pathways as
known from cholane derivatives26 or speciﬁcally via steroid
binding sites as known from steroid hormones27. In our study,
the highest biological activity was found among estratriene
derivatives (series 1–11), while cholane derivatives (series 12–14)
were less efﬁcient. De facto, none of the non-steroid-derived
analogs (series 15–20) exhibited antimalarial activity comparable
to the steroid compounds. The IC50 values on P. falciparum
3D7 asexual blood stages were about 2 mM for 17c, 4 mM for 18c,
5.6 mM for 20c,46 mM for 15c and 16c, and 415 mM for 19c.
Notably, 18c is derived from the lipophilic 1-adamantylamine,
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which is closely related to the neuroprotective agent memantine
(3,5-dimethyl-1-adamantylamine). On the basis of these data,
the steroid part is essential for the biological activity of the
compounds. This interesting new chemical entity seems to
vectorize the aminocresols to parasitized red blood cells and
is potentially recognized by transporters. The present study
might therefore initiate new investigations based on the use
of steroids to target not only drugs, but also ﬂuorophores or
other chemical probes, to cells of interest. On the basis of
the properties of our compounds, the sex hormone-binding
globulin (SHBG), the principal carrier of oestrogens
and androgens in the blood of almost all vertebrate species28,
may be involved in drug transport in the in vivo experiments.
Furthermore, in our approach, a lipophilic moiety joined
to a hydrophilic one could result in an inhibitor that might
destabilize cell membranes as known from phosphatidylcholine
inhibitors29,30.
Notably, the 2-hydroxyarylmethylamino-group is present in
all of our best-acting derivatives. Such compounds are well
known for forming ortho-quinone methides of high inherent
reactivity29,31,32. There is some evidence that quinone methide
intermediates, which may alter or inhibit the action of
biomolecules via covalent cross-linking, play a key role (Fig. 5).
In our approach, methylation of the phenolic group (R¼ i and k)
or movement of the OH function to the meta-position (R¼ e)
prevents the formation of quinone methides. Even these
compounds exhibit a clearly decreased antimalarial activity.
Movement of the phenolic group to the para-position recovers
biological activity. Introduction of bulky tert-butyl groups
into ortho- and para-positions prevents cross-linking capability
(6w). All these ﬁndings make a quinone methide mechanism
permitted by R very likely. Furthermore, ortho phenols are most
efﬁcient, while their methyl ethers as well as meta-substituted
phenols are less active (Fig. 5). This fact supports the
participation of a chelation mechanism, including activation
processes and ongoing redox processes mediated by metals. The
recovery of antimalarial activity from meta- to para-substituted
phenols, however, suggests that additional mechanisms are
likely to support activity, as the latter cannot act as bidentate
ligands. Given the lipophilicity of our steroid compounds as
well as their basic nature, it is furthermore most likely that they
access the food vacuole of the parasite. At the pH of the organelle
(5.0), these molecules will be protonated and concentrated.
Protonation of an aminocresol will increase the potential for
a site-speciﬁc formation of a reactive species, limiting any safety
risk. Furthermore, the SAR demonstrates that compounds not
having an aminocresol retain potency (albeit reduced) suggesting
that the structures retain other pharmacology unrelated to this
covalent binding; this is an innovation—delivering a compound
having polypharmacology—with the beneﬁts such as resistance
selection apparent.
When proposing steroid-based compounds as anti-infective
agents, a potential intrinsic biological activity of the steroid
moiety determined by its steric and electronic ﬁt with steroid
binding sites should be considered. In oestrogens, hormone
action is mainly determined by the speciﬁc interaction of the
3- and 17b-OH functions. Both binding sites are impaired
in series 1–8 and 10–11 by 3-OH methylation and in
series 1–6 additionally by the lack of the 17b-OH function.
Therefore, potential side effects based on steroid hormone
activity are unlikely to occur, particularly taking the short-term
course of an antimalarial therapy into account. Furthermore, in
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Figure 5 | Working hypothesis for the mode of action and optimization of R. (a) Ortho-hydroxylated arylmethyl amines exhibit the highest antimalarial
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our experiments no initial liabilities were identiﬁed at high
mM concentrations in vitro and at 100mg kg 1 in vivo in
P. berghei-infected mice. However, more extensive and thorough
testing will be necessary during further preclinical development of
one of the two best compounds or optimized analogues.
Finally, phenoxide binding to haem iron33 might contribute
to the antimalarial effects of our compounds where the
2-hydroxyarylamino moiety may chelate or associate with
metals. For derivatives with this conﬁguration, an increased
antimalarial activity was found compared with the 4-isomer,
which may also furnish quinone methide intermediates but does
not chelate metals. Utilizing metal catalytic effects as a driving
force and their dependence on substitution patterns of quinone
methide precursors have been described in other contexts34
and were studied in detail for our antimalarial compounds
(see above).
The most potent steroid compounds discovered here actually
represent a subclass of aminocresols, a group of antimalarials
that have shown up in various antimalarial studies since the
1940s and include amodiaquine. However, none of these
compounds has so far had a steroid attached. A prominent
example of aminocresols is WR194965 (ref. 35). This compound
has strong antimalarial activity against P. falciparum and
P. vivax and was even taken into human trials. However, since
meﬂoquine was discovered at the same time, WR194965 was
not followed up in detail. This is also the reason why only
limited toxicity data are available. A second example is MK4815
(from Merck), which was also identiﬁed via high-throughput
screening and was found to be orally active in a P. berghei mouse
model, even when applied as a single dose36. However, the
IC50 against P. falciparum 3D7 was about one order of magnitude
higher than that of our steroid-based compounds. Indeed there
are additional theoretical concerns that exist for aminocresols in
general. First, there is the potential for unwanted toxicity
associated to quinone methide formation. Second, depending
on the lipophilicity and the basicity of the compounds, there is
potential for cardiovascular and CNS safety issues. All of these
would need to be carefully monitored in preclinical safety studies
before starting human studies. However, even in reasonably
detailed toxicology studies, the respective compounds, including
our steroid derivatives, have hardly shown any toxicity.
Furthermore, as indicated by initial studies in cell culture using
a genetically encoded redox probe (Supplementary Fig. 8),
the redox stress induced by the steroid compounds might
contribute to their mechanism of action but is unlikely to
represent a major risk for patients with glucose-6-phosphate
dehydrogenase deﬁciency. Interestingly, Jacobus Pharmaceuticals
has recently delivered a second generation WR194965 named
JPC3210 with reported excellent efﬁcacy and half-life37. Much has
already been said about pan-assay interference compounds
(PAINs) that cannot be developed into selective covalently
binding drugs38,39. However, not all compounds with PAIN
characteristics should be discarded a priori as antimicrobial
agents because the compounds are expected to be administered
for rather short-term treatment compared with drugs acting in
other ﬁelds such as the treatment of cancer or cardiovascular
diseases. Although the authors of course fully agree that the
potential safety issues of PAINs need to be taken into account
thoroughly, it is a big challenge to ﬁght dogmas and taboos in the
ﬁeld of anti-infective drug discovery. Furthermore, even
with PAINS characteristics, compounds with excellent potencies
should be considered for chemical probe discovery40 to help
and improve our understanding of drug targets/transporters
and pathways.
The next steps for further optimizing our steroid compounds
include in-depth analyses of pharmacokinetic and toxicological
properties, further improvement of lipophilicity and ADME
properties including oral bioavailability and enhancement of
potency in vivo. One starting point could be the further
optimization of R, for example, by introducing suitable leaving
groups. Furthermore, the potential of combining the steroid
compounds with known antimalarial agents should be system-
atically evaluated. To reduce potential hormone activity a basic
nitrogen function has already been introduced into the
compounds. Further approaches could be taken including
the preparation of analogues with altered substitution patterns
and altered stereochemistry at the gonane core and the
introduction of a second (or third) hydroxyarylmethylamino
group. A more detailed discussion of lead optimization is given in
Supplementary Note 1. On the basis of our studies and
the corresponding considerations we propose here a novel
approach to drug development for ﬁghting malaria, schistoso-
miasis and potentially other parasitic diseases.
Methods
Cultivation of Plasmodium falciparum. The chloroquine-sensitive P. falciparum
strain 3D7 Netherlands and the chloroquine-resistant strain Dd2 (kindly provided
by Michael Lanzer, Heidelberg in 2000) were grown in continuous culture as
described by Trager and Jensen41 with slight modiﬁcations42. Unless otherwise
stated, parasites were maintained at 1 to 10% parasitaemia and 3.3% haematocrit
in an RPMI 1640 culture medium supplemented with Aþ erythrocytes
(purchased from the blood bank of the University Hospital Giessen and
Marburg, UKGM), 0.5% lipid-rich bovine serum albumin (Albumax), 9mM
(0.16%) glucose, 0.2mM hypoxanthine, 2.1mM L-glutamine, and 22mgml 1
gentamicin. All incubations were carried out at 37 C in 3% O2, 3% CO2, and
94% N2 unless otherwise stated. Synchronization of parasites in culture to ring
stages as a starting population was carried out via treatment with 5% (w/v) sorbitol.
The parasites were used for the experiments delineated below.
IC50 values on P. falciparum in vitro and drug combinations. Isotopic drug
sensitivity assays were employed as described41 to investigate the susceptibility
of P. falciparum to the steroid compounds. The procedure depends on the
incorporation of radioactive 3H-hypoxanthine, which is taken up by the parasite as
a precursor of purine deoxynucleotides for DNA synthesis43. In 96-well microtitre
plates (NuncR), a twofold serial dilution of the starting concentration of each
pharmacologically active compound to be tested was carried out. Parasites were
incubated at a parasitaemia of 0.25% (470% ring forms) and 1.25% haematocrit in
hypoxanthine-free medium. After 48 h, 0.5 mCi 3H-hypoxanthine was added to
each well, and the plates were incubated for another 24 h. The cells of each well
were then collected on a glass ﬁbre ﬁlter (Perkin-Elmer, Rodgau-Ju¨gesheim,
Germany), washed, and dried. Their radioactivity in counts per minute was
considered to be proportional to the number of parasites in the well. All IC50 values
were determined at least in quadruple. IC50 values (drug concentrations that
produce 50% reduction in the uptake of 3H-hypoxanthine) were calculated.
IC50 values on P. falciparum gametocytes in vitro. Sensitivity of P falciparum
gametocytes to lead compound 1o was determined by measuring the activity of
luciferase in luciferase-expressing gametocytes after an exposure of 72 h to different
concentrations of compound 1o.
The pfs16-GFP-Luc (NF54 background) parasite strain44 was maintained
at 1 to 10% parasitaemia in an RPMI 1640 culture medium supplemented
with Aþ erythrocytes (2% haematocrit), 10% decomplemented human serum,
9mM (0.16%) glucose, 0.2mM hypoxanthine, 2.1mM L-glutamine, and
20 mgml 1 gentamicin. Parasite cultures were incubated at 37 C in 5% O2,
5% CO2, and 90% N2. Asexual blood stage parasites were ﬁrst synchronized
by 5% D-sorbitol (wt vol 1) treatment for 10min at 37 C for two or more
successive growth cycles. Synchronous parasites at 3% haematocrit were cultured in
10 cm Petri dishes to 10% parasitaemia (ring stage), at which point
gametocytogenesis was induced by feeding cultures with a mixture of conditioned
and fresh media (1:1). The next day, trophozoite cultures were diluted fourfold.
N-acetyl glucosamine (NAG; Sigma-Aldrich) was added to a ﬁnal concentration of
50mM after all schizonts had ruptured. NAG treatment was maintained for the
next two to three cycles of reinvasion to eliminate all asexual forms from the
culture. Immature gametocyte stages (I and II) were puriﬁed on a Percoll
gradient45 and incubated directly in 96-well plates at 9%, 12%, or 45%
gametocytaemia depending on the experiment (150 ml well 1). Gametocyte
cultures were exposed for 72 h to dilutions of compound 1o, methylene blue (MB)
(Sigma M9140) or DMSO (0.5%) starting at day 3, 8, or 11 after gametogenesis
induction. For this, compound 1o (10mM) and MB (10mM) were dissolved in
100% DMSO and H2O, respectively, diluted 1:100 in RPMI, and further diluted in
RPMI to the proper concentrations. 150 ml of these solutions were added to the
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gametocyte culture in triplicate. Following drug exposure, parasites were cultivated
for two additional days in normal medium before centrifugation and freezing at
 80 C, and luciferase activity was measured.
Luciferase assays in P. berghei and P. falciparum in vitro. Plates frozen at
 80 C were thawed at 37 C. The cells were lysed at room temperature in
10ml 1x luciferin lysis buffer (Luciferase Cell Culture Lysis 5 reagent, Promega),
and 100ml luciferase assay substrate was added to each well (Luciferase Assay
System, Promega). Luciferase activity was measured on a luminescence plate reader
(Mithras LB940 luminometer, Berthold Technologies). The mean of the luciferase
activity was calculated for each technical triplicate and normalized as follows:
(Lucx LucRBC)/(Lucsolvent LucRBC) with Lucx and Lucsolvent¼mean luciferase
activity for parasites incubated with compound x and with solvent (DMSO for
1o and PBS for MB), respectively, and LucRBC¼mean luciferase activity of
non-infected red blood cells (background). IC50 values were calculated using
Prism (GraphPad, log(inhibitor) versus normalized response—variable slope) in
three independent experiments for the P. falciparum gametocyte assay and ﬁve for
the P. berghei ex vivo drug assay.
In vivo testing in the P. berghei mouse model. The animal experiments
described here were performed at the Swiss Tropical and Public Health Institute
(Swiss TPH, Basel, Switzerland), they were approved by the Swiss Cantonal
Authorities (‘Kantonales Veterina¨ramt Basel Stadt’) adhering to local and national
regulations of laboratory animal welfare in Switzerland. The best compounds
were tested in the murine P. berghei model essentially as described17–19. The
infection was initiated at day 0 with the P. berghei GFP ANKA malaria strain
(donation from AP Waters and CJ Janse, Leiden University). From donor mice
(female NMRI mice, 18–20 grams (about 3 weeks) from Charles River Germany)
withB30% parasitaemia, heparinized blood was taken and diluted in physiological
saline to 108 parasitized erythrocytes/ml. An aliquot (0.2ml) of this suspension
was injected intravenously into experimental and control groups of mice
(female NMRI mice, 18–20 grams (about 3 weeks) from Charles River Germany).
Usually, in untreated control mice parasitaemia rose regularly to B30% by
day 3 post-infection. Control mice died between days 6 and 7 post infection.
In the experiments described here, however, control animals (n¼ 5) were killed on
day 4 post infection for ethical reasons.
The steroid compounds were prepared at an appropriate concentration as
a solution/suspension in Tween 80/alcohol (7:3, Tween 80 and absolute ethanol,
respectively), followed by a 10x dilution in water. They were administered to
groups of three mice in three doses (24, 48 and 72 h post infection) or four doses
(4, 24, 48 and 72 h post infection). The route of administration was i.p., p.o., s.c. in
a volume of 10ml kg 1.
The degree of infection (parasitaemia expressed in % of infected erythrocytes)
was determined by FACS analysis on day 4 (96 h post infection). The
difference of the mean infection rate of the control group (¼ 100%) to the
test group was calculated and expressed as a percent reduction. For example,
activity determination with a mean of 2% parasitaemia in treated mice and
a mean of 40% parasitaemia in the control animals is calculated as follows:
(40 2%)/40% 100¼ 95% activity. The survival time in days was recorded
up to 30 days after infection. A compound was considered curative if the
animal survived to day 30 after infection with no detectable parasites (conﬁrmed by
light microscopy).
In vivo maintenance of P. berghei parasites. The animal experiments described
in this part were performed at the Institut de Biologie Mole´culaire et Cellulaire
(Strasbourg, France), using facilities and protocols adhering to national regulations
of laboratory animal welfare in France. Facilities and protocols have been certiﬁed
by the regional veterinary services (authorization N F67-482-2) and by the
national ethics committee in animal experimentation (authorization N 04480.02),
respectively. 8- to 12-week-old male Hsd:ICR mice (bred in-house from couples
purchased from Envigo) were infected with the P. berghei ANKA malaria strain
constitutively expressing GFP or GFP luciferase46,47. For this, blood was taken by
heart puncture from a donor mouse with a parasitaemia of 3–5%, diluted in
PBS to 108 parasitized erythrocytes per ml. 0.2ml of this suspension was
injected intravenously into mice. Parasitaemia was monitored via FACS analysis
(FACSCalibur, BD Bioscience). The P. berghei parasites maintained in vivo were
then used for the ex vivo drug assay and transmission-blocking assays.
Determination of IC50 values on P. berghei parasites ex vivo. Sensitivity of
P. berghei asexual stages to lead compound 1o was determined by measuring the
activity of luciferase in a parasite expressing constitutively GFP-Luciferase after
an exposure of 24 h to different concentrations of compound 1o in ex vivo
conditions46. Brieﬂy, infected blood was collected by heart-puncture from
a mouse with parasitaemia between 1 and 3%. Blood was washed twice in RPMI
1640 culture medium supplemented with fetal calf serum (FCS) at 25% and
resuspended in the same medium. Infected blood samples were exposed for 24 h to
dilutions of compound 1o and methylene blue (Sigma) (0, 1, 3, 10, 30, 100, and
300 nM) or DMSO (0.2%). For this, compound 1o (10mM) and MB (10mM) were
dissolved in 100% DMSO and H2O, respectively, diluted 1:100 in RPMI, and
further diluted in RPMI to the proper concentrations. 50 ml of these solutions
were added to each well containing 50 ml of infected blood (ﬁnal haematocrit 2%)
in triplicate. The plate was incubated for 24 h at 37 C in 5% O2, 5% CO2 and
90% N2; supernatant was removed before freezing at  80 C; and luciferase
activity was measured.
In vivo transmission-blocking assay. Anopheles gambiae mosquitoes
(G3 strain, donation from the Kafatos laboratory at EMBL in 2002) were bred
following standard procedures48.
Compound 1o was prepared in solution/suspension in Tween 80/absolute
alcohol (7:3), followed by a 10x dilution in water to reach the ﬁnal concentration of
10mgml 1. ProveBlue (Inresa Pharma), a heavy metal-free solution of MB
(5mgml 1) was used as a positive control. Both solutions were injected i.p. in
infected mice as daily doses (24, 48 and 72 h post passage) (100mg kg 1 for
1o and 15mg kg 1 for MB). Negative control mice were i.p. injected with an
equivalent quantity of solvent.
Parasitaemia was determined daily via FACS analysis (FACSCalibur, BD
Bioscience). In parallel, groups of 40 Anopheles gambiae mosquitoes (4–7 days old)
were allowed to take a blood meal on treated and control infected mice
(see paragraph ‘In vivo maintenance of P. berghei parasites for ex vivo drug
assay and transmission-blocking assay’) at 48, 72, 96 and 120 h post infection
(one group of 40 mosquitoes per mouse per day). For this, mice were anaesthetized
via an i.p. injection of 5% Rompun (Xylazine) and 10% Imalge`ne (Ketamine)
diluted in saline solution (100 ml per 10 g) and exposed to mosquito bites for
15min. Fully engorged mosquitoes were sorted, and their midgut was dissected in
1 PBS at 7 days post infection. Each midgut was imaged using a Nikon
ﬂuorescence microscope AZ100, and ﬂuorescent parasites (oocyst stage) were
counted using the Image J watershed program. The prevalence (percentage of
infected mosquitoes) and infection level (average number of parasites per midgut
in mosquitoes carrying at least one parasite) were plotted using Prism. Three
independent experiments were performed, and signiﬁcance for differences between
treatments was calculated using generalized linear models with treatment, time
and repeats as variables using the JMP software (SAS). Data were modelled with
normal distributions and an identity link for parasitemia, a logit link for
prevalence, and a log link for the level of infection.
Inhibition tests on bacteria and yeast. The following organisms were tested at
the Hans Kno¨ll Institute in Jena, for their susceptibility to the compounds 1o and
2o: Bacillus subtilis JMRC:STI:10880, Staphylococcus aureus JMRC:ST:10760,
Escherichia coli JMRC:ST:33699, Pseudomonas aeruginosa JMRC:ST:33772,
Pseudomonas aeruginosa JMRC:ST:337721, Staphylococcus aureus JMRC:ST:33793
(multi-resistant), Enterococcus faecalis JMRC:ST:33700 (Vancomycin-resistant),
Mycobacterium vaccae JMRC:STI:10670, Sporobolomyces salmonicolor
(Basidiomycetes yeast) JMRC:ST:35974, Candida albicans (Ascomycetes yeast)
JMRC:STI:25000, Penicillium notatum JMRC:STI:50164.
The bacteria were propagated in Mueller Hinton Broth (Oxoid)49. Yeast was
propagated in YPD (yeast extract peptone dextrose): 1% yeast extract, 10 g;
2% peptone, 20 g; 2% agar, 20 g; 2% dextrose (glucose), 20 g; Sigma-Y1375. All
bacteria and yeast suspensions were freshly made. The cultures were incubated at
37 C for 16 h. Afterwards, the bacteria concentration from each culture was
determined, and 34ml of nutrient agar was loaded with 107 cells. These cultures
were stored at 6-8 C and could be used for seven days for the preparation of test
plates. 34ml of nutrient agar was liqueﬁed and inoculated with the calculated
amount of inoculum bacteria suspension at 48–50 C, a temperature suitable for
vegetative forms of bacteria. The inoculated nutrient media (34ml each) were
immediately poured into the prepared test plates (3mm layer). With a punching
device, 12 holes per test plate were punched out. For inhibiting bacterial growth,
ciproﬂoxacin was used as a reference substance. The test substances were dissolved
in distilled water, and 5 mgml 1 and 50ml was added to each bacterial culture.
For inhibition of fungal growth, amphotericin B served as the reference substance.
The test substances were diluted to 10 mgml 1 in DMSO/methanol; 50 ml was
added to each culture.
Bacterial growth inhibition assay. Conﬁguring the test plate; volumes/punched
hole: 50ml; test solutions/test plate: 1 50 ml reference substance. Test plates were
cultivated for 18 h at 37 C. Analysis: Reading the inhibition zones (IZ): As IZ, the
zone in which no growth can be determined with the naked eye is measured; the
tiniest colonies on the edge of the inhibition zone were therefore not taken into
consideration. The diameter (f) of the IZ is measured in mm. The analysis of
IZ f is carried out internationally with the help of statistic procedures, especially
regression analysis. With each test approach, the reference substance was brought
along as a control; if there were deviations from allowed IZ f, the test was
repeated. An analysis at 50 mg test substance/diffusion zone showed the following:
 1¼ attempt not measurable; 0¼ no effect; IZ f 15–20mm¼ 1 moderate effect;
21–25mm¼ 2 good effect;425mm¼ 3 very good effect.
The inhibition of bacterial growth was determined using bacterial cultures
grown in Mu¨ller-Hinton Bouillon, which was conﬁgured at barely visible opacity
with the McFarland Standard Nr. 0.5, which indicates a bacterial density of
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108ml 1. This bacterial suspension was diluted with Mu¨ller-Hinton Bouillon
using 2-fold dilution series in the agar diffusion test.
Analysis: The growth in the inhibition zones around the holes containing
active substances is thereby compared with the growth in the growth control
(no active substance). Bacterial growth was determined according to four
measurements: p¼ presence of colonies in the inhibition zone, P¼ presence of
many colonies in the inhibition zone, A¼ indication of inhibition, F¼ facilitation.
Spore inhibition test. The following test organisms were used for their suscept-
ibility to compounds 1o and 2o: Alternaria alternata JMRC:SF:09317, Arthroderma
benhamiae JMRC:ST:35888, Aspergillus fumigatus JMRC:Afum:00073¼ATCC
46645, Aspergillus terreus JMRC:SF:06307, Candida albicans JMRC:ST:35864,
Lichtheimia corymbifera JMRC:SF:09682, Penicillium chrysogenum
JMRC:SF:10137, Rhizopus arrhizus (syn. R. oryzae) JMRC:SF:05857¼ATCC
56536, CBS 112.07.
Fungi were grown on 3% malt extract solidiﬁed medium for 1 to 2 weeks at
room temperature. Then the plates were washed with 7ml sterile distilled water,
and the spore suspension was ﬁltered through 4 layers of sterile Miracloth
(Kalbiochem, USA) to remove the hyphae. The concentration of the spore
suspension was set to 2 104 conidia ml 1 for the in vitro assays.
The spore inhibition assay took place in 96-well microplates (ﬂat base). 50 ml of
the prepared spore suspension was seeded and then mixed with 50 ml of the
respective inhibitor substance. Tests were started with end concentrations of
1mgml 1 and were then reduced in a minimum of 10 halving steps. Thus
a 2mgml 1 stock solution diluted in half ten times with solvent (distilled water,
2% DMSO in distilled water, or 2% DMF in distilled water) and each 50 ml was
transferred to 50ml spore suspension. For each test substance, 12 holes on the
microtiter plate were ﬁlled. After 24 h incubation (25 C), the germination of the
spores was macroscopically and microscopically examined directly in the microtiter
plate via measurement of the optical density and light microscopy using an inverse
stereomicroscope with subsequent photodocumentation, respectively. If necessary,
the plates were further incubated for another 24 or 48 h, depending on the extent
of fungal germination. The germination was completely inhibited if no mycelium
development occurred.
Schistosome in vitro culture including inhibitor treatment and subsequent
morphological analysis. To maintain the life-cycle of S. mansoni (in-house
Liberian strain)50, Biomphalaria glabrata was used as an intermediate snail host
and the Syrian gold hamster as the ﬁnal host (Mesocricetus auratus; males and
females; 8 weeks old at the time of infection; purchased from Janvier, France).
Adult worms were recovered from hamsters via hepatoportal perfusion 49 days
post infection using M199 medium (Gibco) as described previously20,50.
Experiments with hamsters were done in accordance with the European
Convention for the Protection of Vertebrate Animals Used for Experimental and
Other Scientiﬁc Purposes (ETS No 123; revised Appendix A) and had been
approved by the Regional Council (Regierungspra¨sidium) Giessen (V54-19 c 20/15
c GI 18/10).
Following perfusion, worm couples were collected using featherweight tweezers
and washed with M199 medium before keeping in culture in M199 supplemented
with FCS (Gibco; 10%), HEPES (Sigma; 1M, 1%), and antibiotic/antimycotic
mixture (Sigma; 1%) at 37 C and 5% CO2 (5). Inhibitor treatment was performed
up to 14 days with 1–100 mM of each of the compounds 1c or 1o. Control couples
were kept in culture for the same time periods without adding the compound, but
otherwise they were treated using the same conditions. During the treatment
periods, pairing stability, egg production, and vitality were monitored daily. Pairing
stability of schistosome pairs was approved when males kept their female partners
within the gynecophoral canal while being sucked with their ventral suckers to the
Petri dish. Egg production was determined via bright-ﬁeld microscopy, counting
eggs each day. Separation of couples and detaching from the Petri dish and/or if
worms were lying on their sides were evaluated as signs of decreasing vitality.
Absence of motility and/or gut peristalsis were judged as signs of death.
Selected samples were morphologically analysed via confocal laser scanning
microscopy (CLSM) using a Leica TSC SP2 microscope, a 488 nm He/Ne laser,
and a 470 nm long-pass ﬁlter in reﬂection mode as described earlier (3, 5). In short,
worm couples were prepared via ﬁxation for at least 24 h in AFA (ethanol 95%,
formaldehyde 3%, and glacial acetic acid 2%), stained for 30min with 2.5%
hydrochloric carmine (Certistain, Merck), and destained in acidic 70% ethanol.
After dehydration for 5minutes in 70, 90 and 100% ethanol, worms were preserved
as whole-mounts in Canada balsam (Merck) on glass slides.
Cytotoxicity and antiproliferative effects on mammalian cells. Compounds
were tested for their antiproliferative activity on HUVEC and K-562 cells and for
cytotoxicity on HeLa cells using standard protocols. K-562 (DSM ACC 10),
HUVEC (ATCC CRL-1730), and HeLa (DSM ACC 57) cells were cultured as
described previously51. To assay the antiproliferative and cytotoxic effect,
procedures were carried out as described before12. In brief, for each experiment
with K-562 and HeLa B10,000 cells were seeded per well of the 96-well
microplates. For the cytotoxicity assay, the HeLa cells were preincubated for
48 h without the test substances. Cells were incubated for 72 h at 37 C in
a humidiﬁed atmosphere and 5% CO2. Suspension cultures of K-562 in microplates
were analysed by an electronic cell analyzer system CASY 1 (SCHA¨RFE,
Reutlingen, Germany). The monolayer of the HUVEC and HeLa cells were ﬁxed by
glutaraldehyde (MERCK) and stained with a 0.05% solution of methylene blue
(SERVA). After gently washing, the stain was eluted by 0.2ml of 0.33N HCl in the
wells. The optical densities were measured at 660 nm in a microplate reader. The
calculations of the different values of GI50 and CC50 were performed with the
software Magellan (TECAN).
Furthermore, cytotoxicity tests were carried out on immortalized human
hepatocytes, Fa2N-4 cells (XenoTech, cat.no. IFH15), at the Sanford-Burnham
Medical Research Institute. Cells were incubated with a range of concentrations
(0.01–50mM) of compound 1o for 24 h. Cell viability was determined with
cellular ATP levels by using the Luminescence ATP Detection Assay System
(ATPlite 1 step).
Pharmacokinetics. Pharmacokinetic data were obtained for compound 1o at the
Sanford-Burnham Medical Research Institute according to established procedures.
Compound solubility in an aqueous solution was measured using an automated
kinetic solubility method. The concentration of the compound in a saturated
pH-buffered aqueous solution was determined via UV absorbance (250–498 nm)
and compared with the spectra of a precipitation-free reference solution. The
plasma stability of the compound was determined at a single concentration using
species-speciﬁc plasma. The percentage of parent compound remaining after 3 h
was determined via LC-MS/MS. The percentage of compound 1o bound to plasma
proteins was determined through rapid equilibrium dialysis and quantiﬁed via
LC-MS/MS. Metabolic stability of the compound was determined at a single
concentration using species-speciﬁc liver microsomes that contained cytochrome
P450s, ﬂavin-monooxygenases, carboxyl-esterases, epoxide hydrolases, and other
drug-metabolizing enzymes. The quantiﬁcation was carried out via LC-MS/MS.
Membrane permeability of compound 1o was measured using an in vitro model
for the passive transport from the gastrointestinal tract into the blood system.
A double-sink parallel artiﬁcial membrane permeability assay PAMPA, in
a 96-well format was employed.
Data availability. All relevant data are available from the authors on request.
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